Medicare Enrolled
Dr. Akbar Rizvi, MD
Hematology & Oncology · McKinney, TX
Practice pattern: Mixed Practice— Diverse clinical practice across multiple procedure types
Low-engagement
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. Rizvi from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Rizvi? Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Rizvi
Dr. Akbar Rizvi is a hematology & oncology in McKinney, TX, with 20 years in practice. Based on federal Medicare data, Dr. Rizvi performed 94,092 Medicare services across 2,869 unique beneficiaries.
Between the years covered by Open Payments, Dr. Rizvi received a total of $5,754 from 60 pharmaceutical and/or device companies across 283 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in hematology & oncology. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Rizvi is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 20 years in practice▲ Top 9% volume in TX$ $5,754 industry payments
Medicare Practice Summary
Medicare Utilization ↗94,092
Medicare services
Top 9% in TX for hematology & oncology
2,869
Unique beneficiaries
$12
Avg. Medicare payment
Medicare patients only (65+ / disabled) · Not a quality rating · How to read this →
~4,705 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Iron sucrose injection (Venofer) | 34,600 | $0 | $2 |
| Anti-nausea injection (fosaprepitant) | 19,800 | $0 | $5 |
| Pembrolizumab injection (Keytruda) | 13,300 | $43 | $137 |
| Dexamethasone injection (steroid) | 3,952 | $0 | $1 |
| Immune globulin infusion (Octagam) | 3,850 | $34 | $234 |
| Denosumab injection (Prolia/Xgeva) | 2,040 | $18 | $66 |
| Injection, granisetron hydrochloride, 100 mcg | 1,880 | $0 | $24 |
| Injection, leucovorin calcium, per 50 mg | 1,725 | $3 | $25 |
| Anti-nausea injection (Aloxi/palonosetron) | 1,590 | $1 | $114 |
| Complete blood count (CBC) with differential | 1,527 | $8 | $36 |
| Office visit, established patient (30-39 min) | 1,423 | $93 | $368 |
| Comprehensive metabolic blood panel | 1,217 | $10 | $64 |
| Blood draw (venipuncture) | 1,162 | $8 | $20 |
| Injection, fluorouracil, 500 mg | 826 | $2 | $13 |
| Injection of additional new drug or substance into vein | 820 | $12 | $108 |
| Administration of chemotherapy into vein, 1 hour or less | 555 | $97 | $707 |
| Hospital follow-up visit, moderate complexity | 368 | $58 | $247 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 292 | $47 | $313 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 290 | $22 | $157 |
| Injection, zoledronic acid, 1 mg | 202 | $7 | $431 |
| Ceftriaxone antibiotic injection | 196 | $0 | $36 |
| Iron level test | 173 | $6 | $27 |
| Iron binding capacity test | 173 | $9 | $35 |
| Ferritin level test (iron stores) | 171 | $13 | $60 |
| Injection, carboplatin, 50 mg | 152 | $2 | $300 |
| Injection, diphenhydramine hcl, up to 50 mg | 141 | $1 | $7 |
| Administration of additional new drug or substance into vein, 1 hour or less | 137 | $49 | $344 |
| Drug injection, under skin or into muscle | 136 | $11 | $96 |
| Administration of chemotherapy into vein, each additional hour | 116 | $21 | $161 |
| Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l | 109 | $123 | $500 |
| Carcinoembryonic antigen (cea) protein level | 97 | $19 | $99 |
| Microscopic examination for white blood cells with manual cell count | 97 | $4 | $22 |
| Complete blood count (CBC), automated | 97 | $6 | $34 |
| Reticulated (young) platelet measurement | 90 | $35 | $143 |
| Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion | 89 | $15 | $94 |
| Office visit, established patient (20-29 min) | 76 | $53 | $250 |
| New patient office visit (45-59 min) | 74 | $109 | $565 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 72 | $16 | $100 |
| Infusion, normal saline solution , 1000 cc | 66 | $2 | $19 |
| Unclassified drugs | 52 | $1 | $8 |
| Initial hospital admission, high complexity | 50 | $125 | $694 |
| Irrigation of implanted venous access drug delivery device | 49 | $18 | $114 |
| Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 48 | $90 | $657 |
| Initial hospital admission, moderate complexity | 44 | $92 | $470 |
| Nuclear medicine study from skull base to mid-thigh with ct scan | 42 | $1,090 | $4,802 |
| Infusion, normal saline solution, sterile (500 ml = 1 unit) | 31 | $1 | $19 |
| Infusion into a vein for hydration, each additional hour | 29 | $10 | $75 |
| Initial hospital care with straightforward or low level of medical decision making, per day, if using time, at least 40 minutes | 27 | $59 | $348 |
| Immunologic analysis for detection of tumor antigen, quantitative; ca 15-3 | 20 | $20 | $128 |
| Injection of drug or substance into vein | 19 | $28 | $247 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
5.1% high complexity
87.2% medium
7.6% routine
Industry Payment Transparency
Open Payments through 2024 ↗$5,754
Total received (2018-2024)
Avg $822/year across 7 years
Top 41% in TX for hematology & oncology
60
Companies
283
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$4,596 (79.9%)
Other
Charitable contributions, space rental, and other categories
$744 (12.9%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$414 (7.2%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024$1,978
2023$1,371
2022$485
2021$164
2020$269
2019$616
2018$869
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
Novartis Pharmaceuticals Corporation
$1,060
PFIZER INC.
$494
AstraZeneca Pharmaceuticals LP
$310
E.R. Squibb & Sons, L.L.C.
$285
Genentech USA, Inc.
$261
Janssen Biotech, Inc.
$223
Medtronic, Inc.
$221
GENZYME CORPORATION
$173
Gilead Sciences, Inc.
$156
Incyte Corporation
$145
Merck Sharp & Dohme Corporation
$145
Celgene Corporation
$138
Daiichi Sankyo Inc.
$122
Lilly USA, LLC
$115
PharmaEssentia USA Corporation
$111
Seagen Inc.
$105
SANOFI-AVENTIS U.S. LLC
$100
Janssen Pharmaceuticals, Inc
$81
Regeneron Healthcare Solutions, Inc.
$81
Octapharma USA, Inc.
$65
EMD Serono, Inc.
$64
Acrotech Biopharma LLC
$64
Astellas Pharma US Inc
$63
ARRAY BIOPHARMA INC
$62
Sirtex Medical Inc
$55
Kite Pharma, Inc.
$54
Amgen Inc.
$54
Merck Sharp & Dohme LLC
$54
TerSera Therapeutics LLC
$54
Karyopharm Therapeutics Inc.
$49
Clovis Oncology, Inc.
$49
Alnylam Pharmaceuticals Inc.
$45
Genmab U.S., Inc.
$43
AVEO Pharmaceuticals, Inc.
$40
Ipsen Biopharmaceuticals, Inc
$40
Boehringer Ingelheim Pharmaceuticals, Inc.
$38
Stemline Therapeutics Inc.
$38
ADC Therapeutics America, Inc.
$35
Pharmacyclics LLC, An AbbVie Company
$32
Inari Medical, Inc.
$28
Global Blood Therapeutics, Inc.
$26
Sobi, Inc
$26
Seattle Genetics, Inc.
$24
Epizyme, Inc.,
$24
MorphoSys, US Inc.
$23
Rigel Pharmaceuticals, Inc.
$23
TESARO, Inc.
$23
Eisai Inc.
$23
Kyowa Kirin, Inc.
$21
ABBVIE INC.
$21
Secura Bio, Inc.
$20
Blueprint Medicines Corporation
$20
Acrotech Biopharma Inc.
$19
Bayer Healthcare Pharmaceuticals Inc.
$19
GlaxoSmithKline, LLC.
$18
MEDIVATION FIELD SOLUTIONS LLC
$17
Myriad Genetic Laboratories, Inc.
$17
Exelixis Inc.
$16
Mylan Institutional Inc.
$12
Arbor Pharmaceuticals, Inc.
$11
Top 3 companies account for 32.4% of total payments
Associated products mentioned in payments ›
ADCETRIS · AFINITOR · AYVAKIT · Abraxane · Alecensa · Avastin · BELEODAQ · BESREMI · BOSULIF · Bavencio · CALQUENCE · CARVYKTI · COPIKTRA · CREON · CT THROMBECTOMY SYSTEM KIT · CYRAMZA · Cabometyx · DARZALEX · DOPTELET · ELIQUIS · ELREXFIO · EMPLICITI · ENJAYMO · Enhertu · Epkinly · Erleada · FOTIVDA · GAZYVA · GILOTRIF · GIVLAARI · Gliadel · IBRANCE · IMFINZI · INJECTAFER · INLYTA · Imbruvica · JAKAFI · JEVTANA · KEYTRUDA · KISQALI · KYPHON EXPRESS II KYPHOPAK TRAY · Kyprolis · LIBTAYO · LIBTAYO CEMIPLIMAB-RWLC INJECTION · LUMAKRAS · LYNPARZA · Lenvima · MEKINIST · MONJUVI · MYLOTARG · Nplate · Nubeqa · OCTAGAM · OJJAARA · OPDIVO · OSTEOCOOL RF ABLATION SYSTEM · OXBRYTA · Ogivri · Orserdu · PADCEV · PIQRAY · PLUVICTO · PRECISETUMOR · PROMACTA · Padcev · Perjeta · Pomalyst · Poteligeo · REBLOZYL · RYBREVANT · Revlimid · Rezlidhia · Rubraca · SANDOSTATIN · SARCLISA · SIR-Spheres Microspheres · SOMATULINE DEPOT · SPRYCEL · SUTENT · Somatuline Depot · TABRECTA · TAGRISSO · TASIGNA · TAZVERIK · TECENTRIQ · TEPMETKO · TUKYSA · Trodelvy · VARUBI · VENCLEXTA · Vanflyta · WILATE - VON WILLEBRAND FACTOR/COAGULATION FACTOR VIII COMPLEX (HUMAN) · XALKORI · XARELTO · XPOVIO · XTANDI · Yescarta · ZEJULA · ZOLADEX · Zoladex
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Most payments (80%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.
Equivalent to $6 per 100 Medicare services performed
Geographic Context
Hematology & Oncologys within 10 mi
25
Per 100K population
2.2
County median income
$117,588
Nearest hospital
BAYLOR SCOTT AND WHITE MEDICAL CENTER MCKINNEY
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →
Summary
Dr. Rizvi is a mixed practice specialist, with above-average Medicare volume (top 9% in TX), and low-engagement industry engagement, with 20 years of practice experience.
This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →
Frequently Asked Questions
Is Dr. Rizvi experienced with iron sucrose injection (venofer)?
Based on Medicare claims data, Dr. Rizvi performed 34,600 iron sucrose injection (venofer) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Rizvi receive payments from pharmaceutical companies?
Yes. Dr. Rizvi received a total of $5,754 from 60 companies across 283 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Rizvi's costs compare to other hematology & oncologys in McKinney?
Dr. Rizvi's average Medicare payment per service is $12. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Rizvi) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Hematology & Oncologys in McKinney
Browse hematology & oncologys in McKinney ranked by procedure volume and transparency data.
Highest volume
Top Hematology & Oncologys in TX
Hematology & Oncologys ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Hematology & Oncologys in TX
Which TX hematology & oncologys receive the most from drug and device companies.
By company
Novartis Pharmaceuticals Corporation Payments to Doctors
See all physicians who received payments from Novartis Pharmaceuticals Corporation.
By company
PFIZER INC. Payments to Doctors
See all physicians who received payments from PFIZER INC..
By company
AstraZeneca Pharmaceuticals LP Payments to Doctors
See all physicians who received payments from AstraZeneca Pharmaceuticals LP.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology